LONDON, Feb. 13, 2018 /PRNewswire/ --
MediPoint: HPV and EBV Tests - Global Analysis and Market
Forecasts
Summary
Download the full report:
https://www.reportbuyer.com/product/5312374
HPV is a viral infection spread by anal, vaginal, or oral sex or
through touching during sexual activity. The breadth of HPV tests
focus on women as the aetiological role of the infection is
well-established with cervical cancer. Most HPV infections
typically resolve within 12 months however infections persisting
beyond that increase the chance of precancerous or cancerous
lesions. Numerous case studies have linked HPV to cervical
carcinoma and HPV 16 accounts for approximately 50% of cervical
cancer while HPV 18 for 20% (de Sanjose et al.).
GlobalHuman Papilloma Virus (HPV) and Epstein-barr (EBV) market was
estimated at $2.5B in 2017 across the
39 markets covered in this report. By the end of the forecast
period in 2024, it is estimated that the market will grow to
approximately $3.1B at a Compound
Annual Growth Rate (CAGR) of 2.9%.
Key drivers of the HPV and EBV market in the forecast period are
-
- The growing prevalence of HPV related cancers
- Rise in anogenital warts due to increased sexual activity.
North American HPV and EBV market was estimated at over
$635M in 2017for the three markets
(US, Canada, and Mexico) covered in this report. By the end of
the forecast period in 2024, it is estimated that the market will
grow to approximately $0.94Bat a
Compound Annual Growth Rate (CAGR) of more than 5.5%.
European HPV and EBV market was estimated at $0.6B in 2017 across the 21 markets (Austria, Belgium, Czech
Republic, Denmark,
Finland, France, Germany, Greece, Hungary, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, Turkey, and the UK) covered in this report. By
the end of the forecast period in 2024, it is estimated that the
market will grow to approximately over $0.79B at a CAGR of about 4%.
Asia-Pacific (APAC) HPV and EBV
market was estimated to be over $1.3B
in 2017 across the seven markets (Australia, China, India,
Japan, New Zealand, South
Korea, and Taiwan) covered
in this report. By the end of the forecast period in 2024, it is
estimated that the market will grow to approximately $1.8B at a CAGR of over 5%.
South American HPV and EBV market was estimated at $54M in 2017 across the three markets
(Argentina, Brazil, and Chile) covered in this report. By the end of
the forecast period in 2024, it is estimated that the market will
grow to approximately $65.2M at a
CAGRof 2.5%.
Middle East and Africa HPV and EBV
market was estimated at over $50M in
2017 across the five markets (Egypt, Israel, Saudi
Arabia, South Africa, and
United Arab Emirates [UAE])
covered in this report. By the end of the forecast period in 2024,
it is estimated that the market will grow to approximately
$71.3M at a CAGR of about 5%.
The report "MediPoint: HPV and EBV Tests - Global Analysis and
Market Forecasts", focuses on the market outlook for HPV and EBV in
the global market. This report analyzes and discusses the major
drivers and barriers of HPV and EBV testing adoption, and provides
an in-depth understanding of the future outlook for this market by
geography, with an overall emphasis on the current and future
trends in the 39 countries analyzed.
In particular, this report provides the following -
- In-depth analysis of unmet needs and adoption trends of different
HPV and EBV Tests
- Insightful review of the key industry drivers, opportunities,
restraints and challenges.
- Annualized total HPV and EBV Tests market revenue by segment and
market outlooks from 2017-2024.
- Other key topics covered include strategic competitive
assessment, identification of unmet needs, and market dynamics.
Companies mentioned in this report: Abbott, Hologic, Bio-Rad,
Qiagen, Roche
Scope
- Competitive assessment: Currently marketed HPV and EBV Tests and
evolving competitive landscape
- In-depth analysis of unmet needs and adoption trends of different
HPV and EBV Tests
- Insightful review of the key industry drivers, opportunities,
restraints and challenges.
- Annualized total HPV and EBV Tests market revenue by segment and
market outlooks from 2017-2024.
- Other key topics covered include strategic competitive
assessment, identification of unmet needs, and market dynamics.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies
through a review of pipeline products and technologies, and by
identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping
and driving the HPV and EBV Tests market.
- Drive revenues by understanding the key trends, innovative
products and technologies, market segments, and companies likely to
impact the HPV and EBV Tests market in the future.
- Formulate effective sales and marketing strategies by
understanding the competitive landscape and by analyzing the
performance of various competitors.
- Identify emerging players with potentially strong product
portfolios and create effective counter-strategies to gain a
competitive advantage.
- Track device sales in the global and country-specific HPV and EBV
Tests market from 2017-2024.
- Organize your sales and marketing efforts by identifying the
market categories and segments that present maximum opportunities
for consolidations, investments and strategic partnerships.
Download the full report:
https://www.reportbuyer.com/product/5312374
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that
provides all market research reports from top publishers
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: sarah@reportbuyer.com
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com
View original
content:http://www.prnewswire.com/news-releases/medipoint-hpv-and-ebv-tests---global-analysis-and-market-forecasts-300598005.html
SOURCE ReportBuyer